Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385827
Status:
TERMINATED
Last Update Posted:
2014-08-20
First Post:
2006-10-06
Brief Title:
A Safety and Efficacy Study of Siltuximab CNTO 328 in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer HRPC
Sponsor:
Centocor Inc
Organization:
Centocor Inc
Organization Data
Organization:
Centocor Inc
Class:
INDUSTRY
Study ID:
CR012346
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Centocor Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None